Treatment of rat glomerular mesangial cell (GMC) cultures with pancreatic secreted phospholipase A 2 (sPLA 2 -IB) results in an enhanced expression of sPLA 2 -IIA and COX-2, possibly via binding to its specific M-type sPLA 2 receptor. In the current study, we have investigated the expression and regulation of sPLA 2 -IB and its receptor during glomerulonephritis (GN). In vivo we used the well-established rat model of anti-Thy 1.1 GN (anti-Thy 1.1-GN) to study the expression of sPLA 2 -IB and the M-type sPLA 2 receptor by immunohistochemistry. In addition, in vitro we determined the interkeukin (IL)-1b-regulated mRNA and protein expression in primary rat glomerular mesangial and endothelial cells as well as in rat peripheral blood leukocytes (PBLs). Shortly after induction of anti-Thy 1.1-GN, sPLA 2 -IB expression was markedly upregulated in the kidney at 6-24 h. Within glomeruli, the strongest sPLA 2 -IB protein expression was detected on infiltrated granulocytes and monocytes. However, at the same time, the M-type receptor was also markedly upregulated on resident glomerular cells. In vitro, the most prominent cytokine-stimulated secretion of sPLA 2 -IB was observed in monocytes isolated from rat PBLs. Treating glomerular endothelial cells (GECs) with cytokines elicited only weak sPLA 2 -IB expression, but treatment of these cells with exogenous sPLA 2 -IB resulted in a marked expression of the endogenous sPLA 2 -IB. Mesangial cells did not express sPLA 2 -IB at all. The M-type sPLA 2 receptor protein was markedly upregulated on cytokine-stimulated mesangial and endothelial cells as well as on lymphocytes and granulocytes. During anti-Thy 1.1 rat GN, sPLA 2 -IB and the M-type sPLA 2 receptor are induced as primary downstream genes stimulated by inflammatory cytokines. Subsequently, both sPLA 2 -IB and the M-type sPLA 2 receptor are involved in the autocrine and paracrine amplification of the inflammatory process in different resident and infiltrating cells.
During the past 4 years, evidence was accumulated concerning the important roles of low-molecular-weight secreted phospholipases A 2 in inflammatory diseases (for a review, see Granata et al. 1 and Kudo and Murakami 2 ). Among the different sPLA2s, the pancreatic secreted phospholipase A 2 (sPLA 2 -IB) was described to be markedly elevated in the kidney during both experimental and human acute pancreatitis. 3, 4 Moreover, in the circulation of patients suffering from chronic renal failure, sPLA 2 -IB levels were found to be 10-fold higher than in controls.
effect is also independent of the sPLA 2 -IB catalytic activity, but may be mediated by binding of sPLA 2 -IB to the rat M-type sPLA 2 receptor. [8] [9] [10] [11] [12] [13] [14] Based on these in vitro studies, we sought to find out whether sPLA 2 -IB and its M-type sPLA 2 receptor are upregulated during mesangioproliferative glomerulonephritis (GN). The rat model of anti-Thy 1.1 GN (anti-Thy 1.1-GN) has been used for these studies. This model is based on the rat-specific expression of the glycoprotein Thy-1 on GMCs. The recognition of this protein by the specific anti-Thy-1 antibody OX-7 results in a selective complement-dependent lysis of the mesangium, which is subsequently renewed during a mesangial-proliferative response. 15 The acute injury typically occurs between 1 h and 2 days after induction of the disease and is followed by a rapid proliferation of the endothelial and mesangial cells within the injured glomeruli. Neutrophils and ED-1-positive macrophages are also present during the acute lytic phase. 16, 17 The mesangial cell lesion induced by the anti-Thy1.1 antibody is a useful model system to study GMC responses to injury like the expression of a-smooth muscle-specific actin, 18 or the accumulation of extracellular matrix within the mesangium. 19 A major role in the pathogenesis of this experimental disease plays the activation of complement including the assembly of the C5b-9 membrane attack complex. 20 This complex promotes a rapid induction of proinflammatory mediators such as monocyte chemoattractant protein-1 21 macrophage inflammatory protein-2, 22 and, moreover, via cytosolic to nuclear translocation of the transcription factor nuclear factor kappa B, 23 the formation of nitric oxide. As this is the most important, 24 but not sufficient, 25 signal for the induction of the inducible form of nitric oxide synthase, the formation of the C5b-9 membrane attack complex triggers the production of nitric oxide, which is a crucial mediator in the induction of other genes, thus promoting the severity of the disease. [26] [27] [28] [29] [30] Despite its role as a potent inductor of nitric oxide, the C5b-9 complex has no influence on sPLA 2 expression or activity in GECs. 31 The expression and localization of cyclooxygenase (COX) isoforms and cytosolic phospholipase A 2 have been documented in this model of GN in a previous study. 32 This study has also shown that prostaglandins generated through the activation of cPLA 2 and COX-1 and COX-2 are potent mediators of mesangial cell injury. Here, we have observed that the expression of sPLA 2 -IB and its receptor are markedly increased at the mRNA and protein levels during the development of the anti-Thy 1.1-GN, reaching a maximum increase at 6-24 h after induction of the disease and decreasing at later time points. Expression analysis on isolated cells reveals that sPLA 2 -IB is strongly produced by cytokine-activated monocytes and sPLA 2 -IB-activated endothelial cells in a positive feedback loop, but not by activated mesangial cells. On the other hand, the M-type receptor is upregulated by cytokines in resident mesangial and endothelial cells as well as in infiltrating lymphocytes and granulocytes.
RESULTS
Expression of sPLA 2 -IB in rat kidney with anti-Thy 1.1 GN We first investigated the expression levels of sPLA 2 -IB in total extracts of rat kidneys at different time points after Thy-1 induction compared to control kidneys. Semiquantitative ( Figure 1a ) and real-time reverse transcription-polymerase chain reaction (RT-PCR) (Figure 1b) indicate very low levels of mRNA expression in control kidneys. After induction of Thy 1.1 GN, the mRNA expression of sPLA 2 -IB increases, reaching a maximum at 6 h, and then decreases at later time points to return to control levels after 7-14 days. The Western blot analyses were in accordance with a delayed increase in sPLA 2 -IB protein in total kidney extracts after 6 h, reaching maximal steady-state levels at 24 h (Figure 1c ). The two discrete bands observed at about 14 and 15 kDa probably correspond to mature sPLA 2 -IB and its proenzyme. 33 As an control for equal loading of protein, we included Western blot analyses of b-actin (Figure 1d ).
In order to study the location of sPLA 2 -IB protein in rat kidney, we first performed immunohistochemical analysis with a specific rat sPLA 2 -IB antibody, which does not crossreact with recombinant or native sPLA 2 -IIA, sPLA 2 -V, or sPLA 2 -X (Kortesuo et al. 34 and own observations). A weak staining was observed in the glomeruli of control kidney (Figure 2a) , and no staining was found in the surrounding structures of the cortex. In contrast, 6 ( Figure 2b ) and 24 h (Figure 2c ) after the induction of the disease, a strong staining was detectable in the glomeruli. In the vicinity as well as in the interstitium, a weak staining was visible. The negative control without primary antibody gave no staining ( Figure 2d ).
Detection of sPLA 2 -IB in invading immune cells in the kidney
The time course of sPLA 2 -IB upregulation and immunostaining in the kidney sections suggested that early invading immune cells like monocytes and granulocytes 17 may be the primary source for the production of sPLA 2 -IB. Parallel immunostaining of kidney sections with a specific monoclonal anti-rat HIS-48 antibody (Figure 3c ), a surface marker for rat neutrophils, 22 and with the sPLA 2 -IB antibody (Figure 3b ) shows that 6 h after disease induction the neutrophils express sPLA 2 -IB in the glomeruli. Figure 3d shows merging of both stainings. Sections of the control kidneys are negative for HIS-48 as well as for sPLA 2 -IB (Figure 3a) . At 24 h, the staining with HIS-48 antibody was reduced, indicating that the number of neutrophils decreased at later time points (not shown). Before incubation of the sections, it was necessary to block all immunoglobulin (Ig)G of mouse origin present from the OX-7 antibody, which has been used to induce the disease.
Monocytes also invade the glomeruli during the first 24 h. 17 Using the specific monocyte marker ED-1, we observed a strong increase in ED-1-positive cells after 6 h (Figure 3g ) in parallel to the increase in sPLA 2 -IB expressing cells (Figure 3f ). However, approximately half of the ED-1-positive cells are reactive for sPLA 2 -IB (Figure 3h) . Sections of the control kidneys showed not more than 1-2 ED-1-positive cells (Figure 3e ). The negative controls, which have been pretreated with an anti-IgG antibody, gave no signal without the primary antibodies (not shown). To further identify the type of glomerular cells that express sPLA 2 -IB and to study the regulation of sPLA 2 -IB expression under typical inflammatory conditions, we isolated different glomerular and blood cell types and treated them with IL-1b or tumor necrosis factor alpha (TNFa) alone, or with exogenously added sPLA 2 -IB from bovine pancreas and H48Q-sPLA 2 -IB, a catalytically inactive recombinant mutant of the enzyme. First, we studied the expression of sPLA 2 -IB at the mRNA and protein levels in rat glomerular mesangial and endothelial cells under resting, cytokine-treated, or sPLA 2 -IB (wild-type and mutant enzyme)-treated conditions. Unstimulated GECs express low levels of sPLA 2 -IB mRNA, whereas mesangial cells express no sPLA 2 -IB at all (Figure 4a ). In agreement with this result, we could detect by Western blot analysis the mature sPLA 2 -IB protein and its proenzyme in cell culture supernatants of GECs (Figure 4b ), but not in those from mesangial cells. The stimulation of GECs with IL-1b and TNFa did not markedly enhance the expression of sPLA 2 -IB at the mRNA or protein levels. However, exogenously added WT-sPLA 2 -IB as well as H48Q-sPLA 2 -IB strongly induces the expression of the endogenous sPLA 2 -IB-mRNA (Figure 4a ). Western blot analysis was not possible because of a crossreaction of the rat anti-sPLA 2 -IB antibody with the exogenously added sPLA 2 -IB from bovine pancreas (Sigma, Taufkirchen, Germany) as well as with the recombinant mutant H48Q-sPLA 2 -IB. 1-GN, as described in Materials and Methods, rats were killed after 6 or 24 h, and kidneys were fixed in formalin and embedded in paraffin. The same was carried out with kidneys from healthy control rats. Immunohistochemistry was performed in 5 mm sections with the primary antibody against sPLA 2 -IB (1:500) and with alkaline phosphatase-conjugated goat anti-rabbit IgG (1:100) as secondary antibody as described in Materials and Methods. Pictures were taken from the stained sections at a 1:400 magnification. We next analyzed the expression of sPLA 2 -IB in monocytes, lymphocytes, and granulocytes isolated from rat peripheral blood leukocytes (PBLs) under resting conditions or after stimulation with IL-1b for different times. Rat monocytes constitutively express sPLA 2 -IB mRNA ( Figure  5a ) and protein ( Figure 5b ). Interestingly, after IL-1b treatment, mRNA expression decreased, whereas protein secretion into the cell culture supernatant increased. This might indicate that the cells constitutively synthesize, and, under inflammatory conditions, release sPLA 2 -IB while the mRNA is degraded after cytokine treatment.
Another important source for sPLA 2 -IB are granulocytes. The expression of sPLA 2 -IB mRNA is very strong 6 h after the cytokine treatment (Figure 5a ). High amounts of sPLA 2 -IB are found in the lysates of these cells with a maximum at 6 h after IL-1b stimulation (Figure 5b ). b-Actin expression was shown as a loading control (Figure 5c ).
In contrast, in unstimulated lymphocytes sPLA 2 -IB mRNA is not detectable, but it is upregulated at 2 h after IL-1b treatment (Figure 5a ). However, there is nearly no production of protein ( Figure 5b ) and no protein release is detectable by lymphocytes (not shown).
Together, these results suggest that during the early phases of mesangioproliferative anti-Thy 1.1-GN, immune cells carry and rapidly release sPLA 2 -IB protein inside the glomerulus. The sPLA 2 -IB protein subsequently activates the resident cells to further enhance their production by an autocrine loop.
Expression of the M-type sPLA 2 
receptor under inflammatory conditions in vivo and in vitro
Immunofluorescence analysis shows that the sPLA 2 receptor is not detectable in control kidneys (Figure 6a ), although the receptor was previously detected by sPLA 2 -binding assay with labeled OS1 ligand. 35 However, 6 h after anti-Thy 1.1-GN induction, there was a clear staining of receptor protein in distinct cells inside the glomeruli (Figure 6b ).
We next investigated the expression levels of the M-type sPLA 2 receptor in vitro on isolated glomerular mesangial and endothelial cells and on cells isolated from the PBL fraction. Unstimulated primary rat mesangial cells grown in vitro do not express the sPLA 2 Interestingly, we found that lymphocytes also express the M-type sPLA 2 
DISCUSSION
The expression of sPLA 2 -IB was previously found to be increased in the kidney during acute pancreatitis.
3 sPLA 2 -IB was also proposed to trigger the formation of proinflammatory lipid mediators via activation of the mitogen-activated protein kinase cascade and cPLA 2 , 8,9 to stimulate the proliferation of mesangial cells 7 and to activate rat renal mesangial cells via its specific M-type receptor, thereby leading to the expression of proinflammatory enzymes like the inducible nitric oxide synthase 36 and sPLA 2 -IIA. 9 Here we show for the first time that the expression of both sPLA 2 -IB and its receptor is dramatically increased in kidneys during mesangioproliferative anti-Thy 1.1-GN. These data further support the possibility that sPLA 2 -IB behaves as an in vivo ligand for the M-type sPLA 2 receptor. sPLA 2 -IB is most exclusively detected in cells within the glomeruli, as was shown by immunohistochemical analysis, and these turned out to be mostly invading immune cells. The weak staining in the vicinity of the glomeruli and in the interstitium might be owing to sPLA 2 -IB in BM-8 cells and CD3 þ -positive lymphocytes or dendritic cells, respectively, as it has been observed that these types of cells can be found in this area in GN-like kidney injury in mice. 37, 38 We did not elucidate if this staining is owing to sPLA 2 -IB as there was a clearly predominate enzyme expression in the glomerulus covering this marginal effect. In isolated immune cells in vitro, monocytes and granulocytes represent the main source of sPLA 2 -IB. In good agreement with these results, these cells are among the earliest immune cells invading the glomeruli after induction of anti-Thy 1.1-GN. 16, 17, 39 In particular, monocytes constitutively express sPLA 2 -IB mRNA and protein, and this may explain the drastic increase of this enzyme in the kidney extracts after disease induction.
Interestingly, after IL-1b stimulation, sPLA 2 -IB secretion from monocytes is enhanced, whereas sPLA 2 -IB mRNA in these cells is even downregulated. The situation is comparable to that in HIS-48-positive neutrophils, where it was described that sPLA 2 -IB is stored as inactive zymogen, and after cytokine stimulation the precursor and native enzyme are released from these cells. 40 In vivo studies in rat neutrophils about sPLA 2 -IB expression have not yet been performed. Thus, the present study is the first report showing the expression of sPLA 2 -IB in these cells in anti-Thy 1.1-GN. Six hours after induction of the disease, HIS-48-positive neutrophils invade into the glomeruli and start to express sPLA 2 -IB. We could show this as well in in vitro studies with granulocytes isolated from the PBL fraction of rats. Already 3 h after stimulating the cells with IL-1b, they start to express sPLA 2 -IB mRNA, reaching a maximum in production after 6 h. According to this high mRNA expression, the granulocytes contain very high amounts of the enzyme.
We also analyzed the expression of sPLA 2 -IB by resident renal cells under the conditions of a mesangioproliferative type of GN.
Glomerular endothelial cells in vitro express low levels of sPLA 2 -IB mRNA and constantly release small amounts of sPLA 2 -IB protein; however, there is only a weak upregulation after cytokine treatment. This basal sPLA 2 -IB protein expression may explain the weak immunostaining of the glomeruli in the control kidneys for some housekeeping functions. By treating the endothelial cells with exogenously added sPLA 2 -IB, we mimicked the early stages of anti-Thy 1.1-GN when invading immune cells bring in high amounts of sPLA 2 -IB. Under these conditions, we could show a very strong induction of the endogenous sPLA 2 -IB mRNA production. It is possible that the endogenously produced enzyme is acting on its own synthesis via a positive feedback loop as it has already been described for sPLA 2 -IIA in renal rat mesangial cells. 9 Interestingly, the catalytically inactive mutant H48Q sPLA 2 -IB 41 can also induce the endogenous enzyme. This supports our hypothesis that exogenous sPLA 2 -IB exerts its effects on its own synthesis rather receptormediated than via its enzymatic action.
Mesangial cells do not express sPLA 2 -IB mRNA or protein, and thus any staining of sPLA 2 -IB in these cells is most likely owing to endocytosis of extracellular sPLA 2 -IB protein via the M-type sPLA 2 receptor. On the other hand, in this cell type, sPLA 2 -IB together with TNFa-stimulation is able to trigger the expression of sPLA 2 -IIA. 9 It has been shown that sPLA 2 -IIA enhances the proliferation response of these cells. Furthermore, sPLA 2 -IIA has been demonstrated in high amounts at the lesions of inflammation in damaged glomeruli and a high content of the enzyme has also been found in monocytes/macrophages. 42 After induction of Thy1.1-GN, sPLA 2 -IIA mRNA is upregulated in a timedependent manner (data not shown). Taken these facts into account, there is a strong evidence that sPLA 2 -IIA acts as an autocrine and/or paracrine mediator in the progression of GN.
sPLA 2 -IB is the only sPLA 2 subtype known so far to bind with high affinity to the rat M-type sPLA 2 receptor (K D ¼ 0.5 nM; Beck et al. ). Earlier studies in rat mesangial cell cultures have shown that sPLA 2 -IB, independently of its catalytic activity, stimulates the expression of the proinflammatory sPLA 2 -IIA and prostaglandin formation. 8, 12 Recently, we have shown that this process involves the activation of the transcription factor, peroxisome proliferator-activated receptor a, 9 and proposed an important role for the M-type sPLA 2 receptor in this process. In the present study, we show for the first time that the expression of the M-type sPLA 2 receptor is dramatically upregulated at mRNA and protein levels during GN. In particular, resident glomerular cells of the nephritic kidneys express high amounts of the receptor. In vitro, IL-1b-stimulated rat primary mesangial cells show a massive upregulation of the receptor at mRNA and protein level, and thus all the cellular effects observed by exogenously added sPLA 2 -IB in mesangial cells may be augmented in the presence of proinflammatory cytokines owing to an increase in the M-type receptor number.
Interestingly, GECs were found to constitutively express low receptor mRNA and protein levels, which were upregulated after IL-1b treatment. We have observed earlier that human lung microvascular endothelial cells respond to sPLA 2 -IB treatment with a nuclear factor kappa kB-and extracellular signal-regulated protein kinase-1/-2-mediated upregulation of inflammatory chemokines. 44 It is tempting to speculate that GECs, which show an enhanced M-type sPLA 2 receptor expression during inflammatory conditions, respond in a similar manner to the massive increase in sPLA 2 -IB protein by upregulating proinflammatory genes.
Regarding the invading immune cells, we detected a strong upregulation of the M-type sPLA 2 receptor mRNA in IL-1b-stimulated lymphocytes as well as in granulocytes. Concerning the lymphocytes, Yokota et al. 45 made a similar observation at the protein level in lymphocytes of mice spleen during lipopolysaccharide-induced endotoxic shock. During anti-Thy 1.1-GN, lymphocytes appear at 24 h after disease induction, reaching a maximum after 7 days. 46 Thus, an enhanced sPLA 2 -IB expression together with an increased M-type sPLA 2 receptor level in lymphocytes may contribute to inflammatory signaling mechanisms during the delayed progression of GN.
The presence of M-type receptor on neutrophils has been described earlier. 47 According to our data on the strong induction of the M-type sPLA 2 receptor mRNA together with the production of high amounts of sPLA 2 -IB in granulocytes, this cell type might be responsible for the very early onset of anti-Thy 1.1-GN cell damage.
Because of its internalization properties, 48 the M-type sPLA 2 receptor may play a role in the clearance of sPLA 2 -IB from the extracellular fluid. On the other hand, we have recently shown that the activation of peroxisome proliferatoractivated receptora by sPLA 2 -IB in rat mesangial cells enhances the cytokine-stimulated induction of the proinflammatory sPLA 2 -IIA by a mechanism independent of its catalytic activity and possibly via the M-type sPLA 2 receptor and activation of cPLA 2 .
9 sPLA 2 -IB may therefore indirectly mediate the formation of endogenous lipids that serve as ligands for peroxisome proliferator-activated receptor a activation in rat mesangial cells via activation of cPLA 2 and eicosanoid-generating enzymes (Beck et al. 9 and citations herein), and thereby may contribute to the onset of inflammatory processes. 49 The development of specific sPLA 2 receptor antagonists might be a new therapeutic approach for the treatment of mesangioproliferative GN.
MATERIALS AND METHODS Materials IL-1b was obtained from Cell Concept (Umkirch, Germany). TNFa was a generous gift from Knoll AG (Ludwigshafen, Germany). Horseradish peroxidase-conjugated goat anti-rabbit IgG was from Amersham-Pharmacia (Freiburg, Germany). Immobilon-polyvinylidine difluoride membranes were obtained from Millipore (Eschborn, Germany). Skim milk powder was obtained from Sigma (Taufkirchen, Germany). All other chemicals used were from either Sigma, Biomol (Hamburg, Germany) or Calbiochem (Bad Soden, Germany). All cell culture media and nutrients were from Invitrogen (Eggenstein, Germany). Goat serum was obtained from SantaCruz Biotechnology (Heidelberg, Germany), Proteinase K from Qiagen (Hilden, Germany), and DAKO Fluorescent Mounting Medium from DAKO-corporation (Hamburg, Germany). Anti-rat neutrophil antibody HIS-48 and anti-monocyte antibody ED-1 were a kind gift from Dr P Heeringa (University of Maastricht, The Netherlands). The polyclonal antibody against rat sPLA 2 -IB was generated in rabbit as described earlier 3, 34 and was diluted in 50% glycerol. Rabbit anti-serum directed against the mouse M-type receptor was prepared by immunizing the rabbit with 100 mg of purified soluble mouse M-type receptor produced as described previously for the rabbit soluble M-type receptor. 50 Anti-mouse IgG antibody produced in goat was obtained from R&D Systems (Wiesbaden, Germany) and anti-b-actin antibody produced in mouse from Sigma, Biomol (Hamburg, Germany). Recombinant sPLA 2 -IB and the mutant form sPLA 2 -IB-H48Q were produced as described (6) , and porcine and bovine sPLA 2 -IB were purchased from Sigma Biomol (Hamburg, Germany). All enzymes were endotoxin-free as tested by the Limulus amebocyte lysate assay from BioWhittaker (Wakersville, MD, USA).
Experimental model and experimental design of anti-Thy 1.1-GN in rats All animal studies were approved by the Institutional Review Board. Anti-Thy-1.1 mesangial proliferative GN 20 was induced in male Wistar rats (Charles River, Sulzfeld, Germany), weighing 140-160 g at the start of the experiment, by injection of 1 mg/kg monoclonal anti-Thy-1.1 antibody (clone OX-7; European Collection of Animal Cell Cultures, Salisbury, UK). The animals were killed at different time points (0, 2, 6, 24 h, 7 days, 14 days) with n ¼ 3 for each time point. The kidneys were used for the isolation of RNA and protein or were formalin-fixed for preparation of paraffin sections.
Cell culture
Primary rat mesangial cells were isolated, cultured, and characterized as described for mouse mesangial cells, except that b-mercaptoethanol was omitted. 51 Cells were grown in Rosewell Park Memorial Institute media 1640 supplemented with glutamax I and 10% fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 mg/ml), non-essential amino acids, 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid buffer (25 mM), and bovine insulin (0.66 U/ml), and used for experiments between passages 12 and 16. Twenty-four hours before stimulation and during the experiments, cells were incubated in serum-free Rosewell Park Memorial Institute media (see above) containing 0.1 mg/ml fatty acid-free bovine serum albumin (BSA).
Rat GECs were cultured as described 52 in Dulbecco's modified Eagle's medium with 10% FCS, penicillin (100 U/ml), streptomycin (100 mg/ml), and bovine insulin (0.66 U/ml). One hour before stimulation and during the experiment, cells were incubated in the same medium but with reduced serum content (2.5% FCS).
Rat peripheral blood leukocytes (PBL fraction) were obtained from fresh heparinized rat blood. One part of Ficoll was covered with two parts of diluted blood (1:2 with phosphate-buffered saline (PBS)) and centrifuged for 20 min at 1 600 r.p.m. Monocytes and lymphocytes from the PBL fraction were isolated by three rounds of centrifugation (10 min at 2200 r.p.m., then 1600 r.p.m., then 1000 r.p.m.) and washing with PBS. Monocytes and lymphocytes were separated by negative immunoselection with a CD-4 isolation kit (Miltony Biotec, Bergisch-Gladbach, Germany) and adherence to plastic dishes, respectively. Lymphocytes represent most of the cells from the non-adherent cell fraction. Each cell fraction was cultured in 10% FCS for 2 days, starved in 1% FCS, and then treated for 2, 6, and 24 h with IL-1b.
For the isolation of granulocytes, the supernatant from the first centrifugation step was removed, and cells from the bottom layer of the Ficoll gradient were taken. The cells were diluted with 4 ml of PBS and 1 ml of 5% dextran solution per 2.5 ml heparinized blood. This suspension was transferred into a glass tube and sedimented for 45 min. The supernatant was transferred carefully into a fresh tube and centrifuged for 10 min at 1000 r.p.m. The pelleted cells were resuspended in 1 ml of ice-cold distilled water, mixed for 20 s, washed with PBS, and centrifuged for 10 min at 1000 r.p.m. The resulting cell pellet was resuspended in medium for further experiments.
Immunohistochemical analysis
Kidney sections embedded in paraffin were de-waxed (2 Â 5 min in xylene), re-hydrated in 100 and 96% ethanol (each 2 Â 10 min), double-distilled water (1 Â 5 min), and then equilibrated in PBS. For demasking the protein surface, sections were incubated with proteinase K (1.5 mg/ml) for 10 min, washed with PBS and treated with 15% goat serum/PBS for blocking. The slides were incubated for 12 h at 41C with or without anti-rat sPLA 2 -IB antibody diluted 1:500 in 15% goat serum/PBS. The sections were then rinsed three times with PBS and incubated at room temperature for 35 min with an alkaline phosphatase-conjugated goat anti-rabbit IgG secondary antibody diluted 1:100 in 2% BSA. The sections were rinsed as described above and incubated in DAKO alkaline phosphatase fast red substrate-chromogen system (DAKO-corporation, Hamburg, Germany), containing fast red tablets, buffered substrate, and levamisole. The staining time was controlled by microscopic observation. Finally, the alkaline phosphatase-labeled sections were counterstained with hematoxylin.
Immunofluorescence Studies
Paraffin sections were prepared as described above. In the case of the kidney sections from animals treated with the anti-Thy-1.1 antibody, it was necessary to block the IgG binding sites of mouse origin with an anti-mouse IgG antibody (c ¼ 0.5 mg/ml) for 12 h at 41C before the use of the monoclonal antibodies against HIS-48 and ED-1. This pretreatment prevents false-positive signals, which are owing to the binding of the Alexa 594-conjugated goat anti-mouse IgG to the anti-Thy-1.1 antibody. After washing for 30 min, we proceeded with adding the appropriate antibody as described below. The slides were incubated for 12 h at 41C either with antibodies against sPLA 2 -IB (1:400), HIS-48 (1:2), ED-1 (1:2), or M-type sPLA 2 receptor (1:10), respectively. All antibody dilutions were prepared in 15% goat serum/PBS. As a negative control, sections were incubated with 15% goat serum/PBS omitting the primary antibody but not the blocking reaction with the anti-mouse IgG antibody. After washing with PBS, the sections were incubated for 30 min at room temperature with 1:400 dilutions (in 15% goat serum/PBS) of the appropriate secondary antibodies carrying a fluorescent label. Alexa 488-conjugated goat anti-rabbit IgG was used for the detection of sPLA 2 -IB and M-type sPLA 2 -receptor. For colocalization studies, the sections were incubated simultaneously with an Alexa 594-conjugated goat anti-mouse IgG diluted 1:400 for the detection of HIS-48-or ED-1-positive cells. Finally, the sections were washed with PBS and embedded in mounting medium. Pictures were taken by using a confocal laser scanning microscope (Zeiss Axiovert 100M/LSM 510).
Semiquantitative RT-PCR Expression of the desired mRNAs was analyzed by semiquantitative RT-PCR using 5 mg of total RNA. First-strand cDNA was prepared with SuperScript II RNase H-reverse transcriptase (Invitrogen, Eggenstein, Germany) and oligo(dT) 15 primer (Promega, Mannheim, Germany) for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) standardization or random hexamer primers (Applied Biosystems, Darmstadt, Germany) for 18S RNA standardization. PCR was performed on a Perkin-Elmer Thermal Cycler using a prepared Mastermix containing deoxynucleoside triphosphates, specific primers, and Red Taq polymerase (Sigma, Taufkirchen, Germany). For the PCR reactions, the following primer sequences were used: sPLA 2 The following PCR conditions were used: sPLA 2 -IB -941C for 4 min (one cycle) followed by 941C for 1 min, 561C for 60 s, 721C for 3 min (30 cycles), and a final extension at 721C for 10 min. M-type sPLA 2 receptor -941C for 1 min (one cycle), followed by 941C for 1 min, 601C for 1 min, 721C for 1 min (28 cycles), and a final extension at 721C for 10 min. GAPDH -941C for 1 min (one cycle) followed by 941C for 1 min, 601C for 1 min, 721C for 2 min (23 cycles), and a final extension at 721C for 10 min. 18S RNA -951C for 4 min (one cycle) followed by 951C for 1 min, 601C for 1 min, 721C for 2 min (24 cycles), and a final extension at 721C for 10 min. The amplified PCR products were separated on 1.0% agarose gels containing 0.5 mg/ml ethidium bromide.
Quantitative real-time PCR Total RNA was isolated using Trizol-Reagent (Invitrogen, Eggenstein, Germany) according to the manufacturer's instructions. DNase digestion was performed before reverse transcription to exclude amplification of genomic DNA. Five hundred nanograms of total RNA was reverse transcribed into cDNA according to the manufacturer's instructions (Roche, Mannheim, Germany), using the first-strand cDNA synthesis kit. cDNA was diluted in 20 ml diethyl pyrocarbonate-treated water and stored at À301C until quantitative real-time PCR was performed with a Light Cycler (Roche, Mannheim, Germany). The oligonucleotides of sPLA 2 -IB used for real-time PCR are listed above. Specific DNA standards were generated by PCR amplification of cDNA, purification of the amplified products, and quantification by spectrophotometry. Realtime PCR of cDNA specimen and DNA standards were performed in a total volume of 25 ml, containing 2 ml FastStart DNA Master SYBR Green I, 10 pmoles of gene-specific forward and reverse primers, 2 mM MgCl 2 , and 11.5 ml of water. The amplification profile for each sample was as follows: 2 min at 501C, 5 min at 951C followed by 45-55 cycles of amplification; each amplification cycle consisting of denaturation at 951C for 15 s and annealing/extension at 60/721C for 1 min. Standard curves were generated for all genes. PCR efficiency was assessed from the slopes of the standard curves and was found to be between 90 and 100%. The linearity of the assay could be demonstrated by serial dilution of all standards and cDNA. All samples were normalized for an equal expression of GAPDH. Each experiment was repeated three times with similar results.
Western blot analysis sPLA 2 -IB protein was detected by Western blot after precipitating a 2 ml sample of cell culture supernatant from GECs, mesangial cells, lymphocytes, or monocytes with 800 ml of 20% trichloroacetic acid. Protein lysates from rat kidneys were prepared by homogenizing the tissue by sonication in a buffer consisting of 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 10 mg/ ml leupeptin. The same buffer and conditions were used for preparing protein lysates from harvested cells. Three micrograms of sPLA 2 -IB from porcine pancreas (Sigma, Taufkirchen, Germany) were loaded as a positive control. The protein samples were boiled (5 min, 951C) before loading. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis using a 15% polyacrylamide gel was performed under reducing conditions with 25 mM dithiothreitol in 2 Â Laemmli buffer. The proteins were transferred to Immobilonpolyvinylidine difluoride membranes for 45 min at 0.7 mA/cm 2 . Nonspecific binding was blocked with 2% BSA in PBS/0.05% Tween-20 for 1 h at room temperature followed by incubation with a polyclonal antibody raised against rat sPLA 2 -IB 3 at a 1:1000 dilution in 2% BSA in PBS/0.05% Tween-20. The blot was then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (Amersham Pharmacia Biotech, Freiburg, Germany) at a 1:15 000 dilution in 2% BSA in PBS/0.05% Tween-20 for 1 h at room temperature. The washing steps were performed in 0.05% Tween-20 in PBS. After washing, peroxidase activity was detected by using the chemiluminescence system enhanced chemiluminescence (Amersham Pharmacia Biotech, Freiburg, Germany) according to the manufacturer's instructions.
To analyze the expression of the M-type sPLA 2 -receptor, rat glomerular endothelial and mesangial cells were lysed by sonication (10 s, 20% on a Braun Sonifier) in a buffer consisting of 20 mM Tris/ HCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethyleneglycol tetraacetate, 0.25 mg/ml leupeptin, and 0.1 mM phenylmethylsulfonyl fluoride (pH 7.5). The cell lysates were centrifuged for 5 min at 4000 r.p.m. to remove cellular debris. Homogenates of rat kidney were prepared in the same lysis buffer. Two nanograms of recombinant soluble mouse M-type sPLA 2 receptor were used as a positive control. For Western blot analysis, protein samples were separated on a 7% polyacrylamide gel under non-reducing conditions without boiling before loading. Transfer of the proteins to Immobilon-polyvinylidine difluoride membrane was performed for 60 min at 0.7 mA/cm 2 . Then, the blot was washed twice with distilled water before overnight blocking at 41C in Tris-buffered saline Tween-20 (TTBS) (20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20, pH 7.6) with 5% milk powder. The following washing and incubation steps were performed at room temperature. The blot was rinsed two times with TTBS and then incubated for 2 h with the anti-mouse M-type sPLA 2 -receptor antibody at a dilution of 1:500 in TTBS. After washing with TTBS (3 Â 10 min), secondary antibody (horseradish peroxidase-conjugated goat anti-rabbit IgG) at a 1:15 000 dilution in TTBS was added for 1 h. Finally, the blot was rinsed with TTBS (3 Â 10 min) and prepared for enhanced chemiluminescence detection, as described above.
As an internal loading control, the membranes of the Western blots of the lysates have been incubated with anti-b-actin antibody produced in mouse (diluted 1:10 000 in blocking buffer) after blocking with 2% BSA in PBS/0.05% Tween-20 for 30 min at room temperature. After washing, the blot has been treated with horseradish peroxidase-conjugated goat anti-mouse IgG (Amersham Pharmacia Biotech, Freiburg, Germany) at a 1:15 000 dilution in 2% BSA in PBS/0.05% Tween-20 for 30 min at room temperature. The washing steps were performed in 0.05% Tween-20 in PBS. After washing, peroxidase activity was detected by using the chemiluminescence system enhanced chemiluminescence.
Statistical analysis
Data are represented as means7s.d. (n ¼ 3) showing one representative experiment of three with similar results. Statistical analysis was performed by Student's t-test. A probability o0.05 was considered as significant. The animal studies concerning the antiThy-1.1 mesangial proliferative GN were performed four times in independent experimental series as described above and the results from one representative series are shown.
